CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Pharma
Original article

CSL und Alentis geben weltweite Partnerschaft zur Entwicklung und Vermarktung von lixudebart für seltene Nieren- und Lebererkrankungen bekannt

PartnershiplixudebartPositive
AI Analysis

Summary

CSL and Alentis Therapeutics announced a worldwide partnership for the development and commercialization of lixudebart for rare kidney and liver diseases. Alentis will receive an initial payment of $355 million and up to $1.2 billion in commercial milestone payments with profit sharing on global revenues.

Outcome Details

worldwide partnership for development and commercialization

Importance:7/10
Sentiment:
0.70
partnershiplicensingrare diseaseglobal collaborationmilestone payments
Related Companies
$BMGL

Read the original article

Published by PR Newswire Pharma on October 5, 2026 10:52 PM

Read Original